Navigation Links
BioBDx to Present at the 2011 BioPharm America Conference
Date:8/31/2011

PLYMOUTH MEETING, Pa., Aug. 31, 2011 /PRNewswire/ -- BioBDx announced today that the Company's Chairman and CEO Byron Hewett will present at the 2011 BioPharm America Conference taking place September 7-9.  BioBDx manufactures and markets the Quotient® System, a tool that objectively measures brain functions related to deficits in response inhibition. The first FDA-cleared application of this platform technology is objective measurement of hyperactivity, impulsivity and inattention as an aid in the assessment of attention-deficit hyperactivity disorder (ADHD).  Mr. Hewett will provide a company overview and update on the Quotient ADHD System on Thursday, September 8 at 4:15 p.m. EDT in the Otis room at the Westin Boston Waterfront Hotel in Boston, MA.

About the Quotient® ADHD TestThe Quotient® ADHD Test measures motion and analyzes shifts in attention state to give an objective picture of the core symptom areas of ADHD.  Clinicians use the Quotient® ADHD Test at the initial visit to assess severity of the three core symptoms of ADHD; hyperactivity, inattention and impulsivity.  Patients may be re-assessed periodically at follow-up visits to guide treatment plans.  The clinician integrates the Quotient® ADHD Test report with information from other assessment tools and the clinical evaluation to help guide the discussion on the treatment plan. For more information about the Quotient® ADHD System, please visit http://www.biobdx.com/products

About BioBehavioral Diagnostics CompanyBioBDx manufactures and markets the Quotient System, a tool that aids in the objective and accurate assessment of neural control functions related to deficits in inhibitory control.  We are dedicated to providing physicians, parents and patients with high-value information to guide personalized strategies and to enhance quality of life for patients with ADHD.  Our vision is to provide accurate tools for the diagnosis and management of neurological and psychiatric conditions, leading to a transformation of behavioral medicine.  Founded in 2006, BioBehavioral Diagnostics is a privately held company.Contacts:BioBDx

Media or Investors:Byron Hewett

Tiberend Strategic Advisors, Inc.Chairman and Chief Executive Officer

212-827-0020484-532-2201

Tamara BrightByron_Hewett@BioBDx.com

tbright@tiberend.com or Claire Sojda csojda@tiberend.com
'/>"/>

SOURCE BioBDx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
8. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. ViroPharma to Present at Three Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals International, ... VRX) ("Valeant") today announced positive results from a ... to assess the safety and efficacy of IDP-118 ... of plaque psoriasis. Within the ... moderate to severe psoriasis, IDP-118 showed statistical significance ...
(Date:12/8/2016)... 8, 2016  EIP Pharma, LLC ( www.eippharma.com ... for neflamapimod (previously code named VX-745), with the ... trials that demonstrated significant Alzheimer,s disease relevant pharmacological ... and Study 303 (6-week treatment) are the subject ... Disease (CTAD) scientific conference in San ...
(Date:12/8/2016)... 2016 A Small Business Innovative Research (SBIR) ... Health (NIH) to Phoenix -based NeuroEM ... The grant will seek to determine an optimal set ... electromagnetic waves to treat Alzheimer,s Disease. The grant will ... possibly treat other neurologic disorders such as Parkinson,s Disease ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... of access for customers and employees that are both engaging and easy to ... Service Smart Technology, the software company revealed today its plans to roll out ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, the ... and consumer health products, today announced that it had joined the Pharmaceutical Supply ... non-profit organization to unite pharmaceutical and healthcare companies that share a vision of ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce ... service for Texas, they are expanding their presence in Dallas. One of the most ... will bring new jobs to the Dallas and Forth Worth market. STAT takes pride ...
(Date:12/8/2016)... City, Ga (PRWEB) , ... December 08, 2016 ... ... moving as soon after surgery as possible. With this in mind, SIGVARIS has ... thrombosis (DVT or blood clot) during bed rest and provide the benefits of ...
Breaking Medicine News(10 mins):